Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development

H. Akaza, K. Aiba, S. Isonishi, O. Ogawa, M. Shibuya, S. Sone, T. Tsuruo, S. Noguchi, S. Hinotsu, S. Kono, O. Mikami, G. Blackledge, B. Vose, D. Stribling

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A survey of cancer treatment in a sample of hospitals > 100 beds conducted in 1998 compared with experience in the US showed that good progress has been achieved in Japan in the screening and early treatment of gastric cancer, and that the prognosis for breast cancer is better than in the West. Although in the past, the cytotoxic therapies available to physicians in Japan vs the West have been different, recent acceleration of regulatory review will result in a convergence of treatment paradigms and some improvement in acute response in many tumour types. However, world wide there is a need for new improved therapies in all cancers evaluated. Particular needs are in the management of NSCLC, advanced disease and cancers which form micrometastases. The eventual hope is that cancer can be turned from a lethal disease into a chronic disease where patients maintain a good QOL. Apart from anti hormonal therapies, the usual approach has been to kill the cancerous cells. However, the new approaches to intervening in the growth and migration of cancerous cells or the host tissue response by molecular targeting offer the promise of achieving a step change in therapy. Although EGF tyrosine Kinase inhibitors such as ZD 1839 have been shown to cause a conventional tumour response in NSCLC, many of these new approaches are unlikely to show a short term response even if they have the capacity to affect tumour development and increase disease free survival. Some compounds will require combination therapy with a conventional cytotoxic or radiotherapy to show their full benefit. For conventional cytotoxics, the usual approach to development has been to select the maximum tolerated dose and then evaluate the efficacy in advanced disease. However, for the new approaches which will not have such severe dose limiting toxicities, it will be necessary to select a surrogate marker of the intended biological effect to select the optimal biological dose (OBD) and dose regimen in phase I/II studies for further evaluation in phase II or III studies which are designed to show the expected patient benefit. The tumour target, the stage of the disease and the possible need for concomitant therapy will also have to be considered according to the mechanism of action of the product.

Original languageEnglish
Pages (from-to)1681-1693
Number of pages13
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume27
Issue number11
Publication statusPublished - Oct 2000
Externally publishedYes

Fingerprint

Drug Delivery Systems
Neoplasms
Therapeutics
Japan
Breast Neoplasms
Neoplasm Micrometastasis
Maximum Tolerated Dose
Epidermal Growth Factor
Protein-Tyrosine Kinases
Disease-Free Survival
Stomach Neoplasms
Cell Movement
Chronic Disease
Radiotherapy
Biomarkers
Physicians
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development. / Akaza, H.; Aiba, K.; Isonishi, S.; Ogawa, O.; Shibuya, M.; Sone, S.; Tsuruo, T.; Noguchi, S.; Hinotsu, S.; Kono, S.; Mikami, O.; Blackledge, G.; Vose, B.; Stribling, D.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 27, No. 11, 10.2000, p. 1681-1693.

Research output: Contribution to journalArticle

Akaza, H, Aiba, K, Isonishi, S, Ogawa, O, Shibuya, M, Sone, S, Tsuruo, T, Noguchi, S, Hinotsu, S, Kono, S, Mikami, O, Blackledge, G, Vose, B & Stribling, D 2000, 'Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 27, no. 11, pp. 1681-1693.
Akaza, H. ; Aiba, K. ; Isonishi, S. ; Ogawa, O. ; Shibuya, M. ; Sone, S. ; Tsuruo, T. ; Noguchi, S. ; Hinotsu, S. ; Kono, S. ; Mikami, O. ; Blackledge, G. ; Vose, B. ; Stribling, D. / Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2000 ; Vol. 27, No. 11. pp. 1681-1693.
@article{53c4943a0d7c442385830f658fdc4f8f,
title = "Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development",
abstract = "A survey of cancer treatment in a sample of hospitals > 100 beds conducted in 1998 compared with experience in the US showed that good progress has been achieved in Japan in the screening and early treatment of gastric cancer, and that the prognosis for breast cancer is better than in the West. Although in the past, the cytotoxic therapies available to physicians in Japan vs the West have been different, recent acceleration of regulatory review will result in a convergence of treatment paradigms and some improvement in acute response in many tumour types. However, world wide there is a need for new improved therapies in all cancers evaluated. Particular needs are in the management of NSCLC, advanced disease and cancers which form micrometastases. The eventual hope is that cancer can be turned from a lethal disease into a chronic disease where patients maintain a good QOL. Apart from anti hormonal therapies, the usual approach has been to kill the cancerous cells. However, the new approaches to intervening in the growth and migration of cancerous cells or the host tissue response by molecular targeting offer the promise of achieving a step change in therapy. Although EGF tyrosine Kinase inhibitors such as ZD 1839 have been shown to cause a conventional tumour response in NSCLC, many of these new approaches are unlikely to show a short term response even if they have the capacity to affect tumour development and increase disease free survival. Some compounds will require combination therapy with a conventional cytotoxic or radiotherapy to show their full benefit. For conventional cytotoxics, the usual approach to development has been to select the maximum tolerated dose and then evaluate the efficacy in advanced disease. However, for the new approaches which will not have such severe dose limiting toxicities, it will be necessary to select a surrogate marker of the intended biological effect to select the optimal biological dose (OBD) and dose regimen in phase I/II studies for further evaluation in phase II or III studies which are designed to show the expected patient benefit. The tumour target, the stage of the disease and the possible need for concomitant therapy will also have to be considered according to the mechanism of action of the product.",
author = "H. Akaza and K. Aiba and S. Isonishi and O. Ogawa and M. Shibuya and S. Sone and T. Tsuruo and S. Noguchi and S. Hinotsu and S. Kono and O. Mikami and G. Blackledge and B. Vose and D. Stribling",
year = "2000",
month = "10",
language = "English",
volume = "27",
pages = "1681--1693",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "11",

}

TY - JOUR

T1 - Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development

AU - Akaza, H.

AU - Aiba, K.

AU - Isonishi, S.

AU - Ogawa, O.

AU - Shibuya, M.

AU - Sone, S.

AU - Tsuruo, T.

AU - Noguchi, S.

AU - Hinotsu, S.

AU - Kono, S.

AU - Mikami, O.

AU - Blackledge, G.

AU - Vose, B.

AU - Stribling, D.

PY - 2000/10

Y1 - 2000/10

N2 - A survey of cancer treatment in a sample of hospitals > 100 beds conducted in 1998 compared with experience in the US showed that good progress has been achieved in Japan in the screening and early treatment of gastric cancer, and that the prognosis for breast cancer is better than in the West. Although in the past, the cytotoxic therapies available to physicians in Japan vs the West have been different, recent acceleration of regulatory review will result in a convergence of treatment paradigms and some improvement in acute response in many tumour types. However, world wide there is a need for new improved therapies in all cancers evaluated. Particular needs are in the management of NSCLC, advanced disease and cancers which form micrometastases. The eventual hope is that cancer can be turned from a lethal disease into a chronic disease where patients maintain a good QOL. Apart from anti hormonal therapies, the usual approach has been to kill the cancerous cells. However, the new approaches to intervening in the growth and migration of cancerous cells or the host tissue response by molecular targeting offer the promise of achieving a step change in therapy. Although EGF tyrosine Kinase inhibitors such as ZD 1839 have been shown to cause a conventional tumour response in NSCLC, many of these new approaches are unlikely to show a short term response even if they have the capacity to affect tumour development and increase disease free survival. Some compounds will require combination therapy with a conventional cytotoxic or radiotherapy to show their full benefit. For conventional cytotoxics, the usual approach to development has been to select the maximum tolerated dose and then evaluate the efficacy in advanced disease. However, for the new approaches which will not have such severe dose limiting toxicities, it will be necessary to select a surrogate marker of the intended biological effect to select the optimal biological dose (OBD) and dose regimen in phase I/II studies for further evaluation in phase II or III studies which are designed to show the expected patient benefit. The tumour target, the stage of the disease and the possible need for concomitant therapy will also have to be considered according to the mechanism of action of the product.

AB - A survey of cancer treatment in a sample of hospitals > 100 beds conducted in 1998 compared with experience in the US showed that good progress has been achieved in Japan in the screening and early treatment of gastric cancer, and that the prognosis for breast cancer is better than in the West. Although in the past, the cytotoxic therapies available to physicians in Japan vs the West have been different, recent acceleration of regulatory review will result in a convergence of treatment paradigms and some improvement in acute response in many tumour types. However, world wide there is a need for new improved therapies in all cancers evaluated. Particular needs are in the management of NSCLC, advanced disease and cancers which form micrometastases. The eventual hope is that cancer can be turned from a lethal disease into a chronic disease where patients maintain a good QOL. Apart from anti hormonal therapies, the usual approach has been to kill the cancerous cells. However, the new approaches to intervening in the growth and migration of cancerous cells or the host tissue response by molecular targeting offer the promise of achieving a step change in therapy. Although EGF tyrosine Kinase inhibitors such as ZD 1839 have been shown to cause a conventional tumour response in NSCLC, many of these new approaches are unlikely to show a short term response even if they have the capacity to affect tumour development and increase disease free survival. Some compounds will require combination therapy with a conventional cytotoxic or radiotherapy to show their full benefit. For conventional cytotoxics, the usual approach to development has been to select the maximum tolerated dose and then evaluate the efficacy in advanced disease. However, for the new approaches which will not have such severe dose limiting toxicities, it will be necessary to select a surrogate marker of the intended biological effect to select the optimal biological dose (OBD) and dose regimen in phase I/II studies for further evaluation in phase II or III studies which are designed to show the expected patient benefit. The tumour target, the stage of the disease and the possible need for concomitant therapy will also have to be considered according to the mechanism of action of the product.

UR - http://www.scopus.com/inward/record.url?scp=0034294692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034294692&partnerID=8YFLogxK

M3 - Article

C2 - 11057319

AN - SCOPUS:0034294692

VL - 27

SP - 1681

EP - 1693

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 11

ER -